VB10.NEO is a wholly owned, DNA-based INT built on Nykode’s proprietary antigen presenting cell (APC)-targeting technology and NeoSELECT, an AI-driven neoantigen selection engine. The preclinical data demonstrates the strength of Nykode’s differentiated APC-targeting, DNA-based vaccine platform, which shows a strong immunogenicity advantage over non-APC-targeted vaccines.

New data showcases further enhanced immune responses with co-administration of molecular adjuvants. VB10.NEO generated robust CD4+ and CD8+ T cell responses across multiple tumor models, demonstrated stronger immune responses than peptide vaccines, durable tumor protection, and improved anti-tumor activity in combination with anti-CTLA4 or anti-PD-L1 antibody checkpoint inhibitors. Nykode is dedicated to leverage AI and machine learning to optimize vaccine design, with new data demonstrating improved antigen secretion and selection of complex antigen designs.

“VB10.NEO is a highly differentiated individualized neoantigen therapy, combining broad, durable immune responses with scalable manufacturing. Together with our new data pointing to further optimized immune responses and further reduced manufacturing timelines, we have strengthened our confidence around VB10.NEO’s potential,” says Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics.